CD8A and neoplasm: Taken together these results show that combination treatment of a protein vaccine and a STINGa promotes both intra-tumoral infiltration of antigen-specific effector CD8 T cells and the functionality of peripheral CD4 T cells, resulting in the inhibition of B16-OVA tumor growth.